Astec LifeSciences Reports Widened Q2 FY27 Consolidated Net Loss Amid Sluggish Revenue
Astec Lifesciences Ltd · Outcome · 26 Oct 2026, 10:26 pm
Astec LifeSciences Reports Widened Q2 FY27 Consolidated Net Loss Amid Sluggish Revenue Astec LifeSciences reported consolidated revenue from operations of ₹7,202.01 lakh for the quarter ended 30th Sep'26, down 2.31% YoY from ₹7,372.06 lakh and 13.81% QoQ from ₹8,356.43 lakh. Consolidated net loss widened significantly to ₹3,739.71 lakh compared to a loss of ₹2,441.70 lakh in Q2 FY26 and ₹1,870.73 lakh in Q1 FY27. Operating margin deteriorated sharply to -27.48% versus -9.07% YoY. Diluted EPS stood at ₹(16.79). Total debt-to-assets remained at 0.42, while net cash generated from operating activities reached ₹12,195.71 lakh for H1 FY27.
Original exchange filing (PDF)
More announcements from Astec Lifesciences Ltd
- Please find enclosed, Company''s response. · 12 Nov 2026
- The Exchange has sought clarification from Astec Lifesciences Ltd on November 11, 2026, with reference to Movement in Volume. <BR><BR>The reply is awaited. · 11 Nov 2026
- Please find attached Press Release · 27 Oct 2026
- Please find enclosed Financials Results for the Quarter and Half year ended . · 26 Oct 2026
- Kindly find attached Outcome of Board meeting · 26 Oct 2026
- Astec LifeSciences Limited has submitted to the Exchange, the unaudited financial results for the quarter and half year ended September 30, 2026. · 26 Oct 2026
- ASTEC LIFESCIENCES LIMITED has informed the Exchange about Board Meeting to be held on 26-Oct-2026 to inter-alia consider and approve the Unaudited Financial results of the Company for the Half Yearly ended September 2026 . · 26 Oct 2026
- Astec Lifesciences Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 26/10/2026 ,inter alia, to consider and approve Please find enclosed intimation. · 26 Oct 2026
